Safety and Immunomodulatory Effects of Siltuximab Prophylaxis Prior to Standard of Care CD19 Directed Chimeric Antigen Receptor T-cell (CD19.CART) Therapy for B-cell Lymphomas: Final Phase I Trial Results

Transplantation and Cellular Therapy 2026

View at publisher
Authors: Nathan Denlinger, NoJoon Song, Negin Goodarzi, Rina Li Welkie, Jungmin Shin, Jordan Edward Krull, Kathleen McConnell, Narendranath Epperla, Jonathan Edward Brammer, Yazeed Sawalha, David Alan Bond, Evandro D. Bezerra
+25 more John C. Reneau, Audrey M. Sigmund, Yun Choi, Walter G. Hanel, Lapo Alinari, Polina Shindiapina, Gabriela Sanchez‐Petitto, Hannah Kyung Choe, Sarah Allison Wall, Jiasheng Wang, Chelsea Peterson, Xiaopei Huang, Beth A. Christian, Sam L. Penza, Robert A. Baiocchi, Kami J. Maddocks, Samantha Mary Jaglowski, Sumithira Vasu, Qin Ma, Dongjung Chung, Mark P. Rubinstein, Zihai Li, Marcos de Lima, Paolo Caimi, Timothy J. Voorhees
DOI: 10.1016/j.jtct.2025.12.031
Cited by: 0

Fields of Study & Subjects

CAR-T cell therapy research Lymphoma Diagnosis and Treatment Immunotherapy and Immune Responses

Publication details

Journal / source
Transplantation and Cellular Therapy
Volume
32
Issue
2
Pages
S15–S17
Publication date
1 February 2026
Language
EN